Additional Information
Market: NYSE
Sector: Medical
Latest Price: 94.76  (0,00%)
52-week High: 109.07
52-week Low: 90.73
Market Cap: 262,400.00M
1 year chart
1 day chart
Johnson & Johnson

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

Johnson & Johnson says new use for blood clot drug Xarelto rejected by FDA

22nd Jun 2012, 9:35 am by Erin Sugar
Johnson & Johnson says new use for blood clot drug Xarelto rejected by FDA

Healthcare giant Johnson & Johnson’s (NYSE:JNJ) division Janssen Research & Development announced late Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve a new use of the company’s blood clot reducer Xarelto, also known as rivaroxaban.

The FDA's Cardiovascular and Renal Drugs Advisory Committee narrowly voted against recommending approval of Xarelto for use in reducing the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

Xarelto is an anticoagulant that works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots.

The drug is approved for three clinical uses in the United States, including reducing the risk of blood clots in the legs and lungs in knee replacement and hip replacement surgery patients, and to reduce the risk of both hemorrhagic and thrombotic strokes in people with atrial fibrillation that is not caused by a heart valve problem.

The FDA issued a complete response letter regarding the new drug application, and Janssen said that it is evaluating the FDA’s response and will respond to the agency’s questions.

"We are confident in the robust study results of the ATLAS ACS 2 TIMI 51 trial and the positive benefit-risk profile of rivaroxaban in patients with ACS," said Janssen’s vice president and cardiovascular franchise medical leader, Dr. Paul Burton.

"We will continue to work with the FDA to fully address their questions as quickly as possible."

ACS is a complication of coronary heart disease that happens when blood clots block a coronary artery, reducing blood supply to the heart.  This blockage could cause a heart attack, or unstable angina that signifies a heart attack may be on its way.

It is the leading cause of death in the United States.

Janssen submitted the supplemental new drug application for Xarelto last December, and received a priority review designation from the FDA in February.

The application included results from its phase 3 ATLAS ACS 2 TIMI 51 clinical trial, which were presented at the American Heart Association annual Scientific Sessions in November 2011.

Janssen is jointly developing Xarelto with Bayer Healthcare. The drug's U.S. marketing rights are held by Janssen Pharmaceuticals.

To date, more than 1.5 million patients have received Xarelto across the globe, with nearly 350,000 prescriptions written for the drug in the United States alone.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here